Research Study

A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Apalutamide Plus Androgen Deprivation Therapy (ADT) Versus ADT in Subjects With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Principal Investigator 
Kim Nguyen Chi

Overview

Body Locations and Systems 
Prostate Cancer
ClinicalTrials.gov# 
NCT02489318
Status 
Recruiting
Study Start/End 
Sep 21, 2015 to Feb 28, 2022
Locations 
Diamond Health Care Centre, Vancouver General Hospital
Name/Title 
Pam Farish, Study Coordinator
Phone 
604-875-4111 ext.68298
Purpose of Study 

The purpose of this study is to determine if the addition of JNJ-56021927 to ADT provides superior efficacy in improving radiographic progression-free survival (rPFS) or overall survival (OS) for participants with low volume mHSPC.

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.